Use of statins and risk of fractures
Use of statins and risk of fractures
Context: Previous studies have reported lower fracture risks in patients taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).
Objective: To investigate risk of fracture among statin users.
Design: Case-control study of data from the General Practice Research Database (GPRD).
Setting: A total of 683 general clinical practices in the United Kingdom.
Patients: Cases were 81 880 patients aged 50 years or older who had a fracture of the vertebrae, clavicle, humerus, radius/ulna, carpus, hip, ankle, or foot occurring between the enrollment date of their practice into the GPRD and July 1999, paired with 81 880 age-, sex-, and practice-matched controls.
Main Outcome Measure: Risk of fracture in current users vs nonusers of statins. Odds ratios were estimated from conditional logistic regression and adjusted for smoking, medications and illnesses associated with fracture risk, and body mass index when known.
Results: The adjusted odds ratio (OR) for current use of statins compared with nonuse was 1.01 (95% confidence interval [CI], 0.88-1.16). For forearm, hip, and vertebral fractures, the ORs were 1.01 (95% CI, 0.80-1.27), 0.59 (95% CI, 0.31-1.13), and 1.15 (95% CI, 0.62-2.14), respectively. Relative to nonuse, a statin dosage of less than 20 mg/d (standardized to simvastatin) was associated with an adjusted OR of fracture of 1.13 (95% CI, 0.96-1.33); this OR was 1.07 (95% CI, 0.82-1.38) at dosages of 20 to 39.9 mg/d and 0.85 (95% CI, 0.47-1.53) at dosages of 40 mg/d or more. The adjusted OR was 0.71 (95% CI, 0.50-1.01) for statin use durations of 0 to 3 months, 1.31 (95% CI, 0.87-1.95) for durations of 3 to 6 months, 1.14 (95% CI, 0.82-1.58) for durations of 6 to 12 months, and 1.17 (95% CI, 0.99-1.40) for durations of more than 12 months.
Conclusion: In this study, use of statins at dosages prescribed in clinical practice was not associated with a reduction in risk of fracture.
1850-1855
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Wegman, Sebastiaan
604d0f4b-a533-4ac5-ad6b-f4eadf5813aa
de Vries, Frank
c6020528-4ac1-4d59-8ab1-8a20c7a6ffda
Leufkens, Bert
6676720e-9f2a-47e2-bad4-2d174b2fbdba
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
11 April 2001
van Staa, Tjeerd-Pieter
f840d545-0e8d-40fe-9124-976826190cc3
Wegman, Sebastiaan
604d0f4b-a533-4ac5-ad6b-f4eadf5813aa
de Vries, Frank
c6020528-4ac1-4d59-8ab1-8a20c7a6ffda
Leufkens, Bert
6676720e-9f2a-47e2-bad4-2d174b2fbdba
Cooper, Cyrus
e05f5612-b493-4273-9b71-9e0ce32bdad6
van Staa, Tjeerd-Pieter, Wegman, Sebastiaan, de Vries, Frank, Leufkens, Bert and Cooper, Cyrus
(2001)
Use of statins and risk of fractures.
Journal of the American Medical Association, 285 (14), .
(doi:10.1001/jama.285.14.1850).
Abstract
Context: Previous studies have reported lower fracture risks in patients taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins).
Objective: To investigate risk of fracture among statin users.
Design: Case-control study of data from the General Practice Research Database (GPRD).
Setting: A total of 683 general clinical practices in the United Kingdom.
Patients: Cases were 81 880 patients aged 50 years or older who had a fracture of the vertebrae, clavicle, humerus, radius/ulna, carpus, hip, ankle, or foot occurring between the enrollment date of their practice into the GPRD and July 1999, paired with 81 880 age-, sex-, and practice-matched controls.
Main Outcome Measure: Risk of fracture in current users vs nonusers of statins. Odds ratios were estimated from conditional logistic regression and adjusted for smoking, medications and illnesses associated with fracture risk, and body mass index when known.
Results: The adjusted odds ratio (OR) for current use of statins compared with nonuse was 1.01 (95% confidence interval [CI], 0.88-1.16). For forearm, hip, and vertebral fractures, the ORs were 1.01 (95% CI, 0.80-1.27), 0.59 (95% CI, 0.31-1.13), and 1.15 (95% CI, 0.62-2.14), respectively. Relative to nonuse, a statin dosage of less than 20 mg/d (standardized to simvastatin) was associated with an adjusted OR of fracture of 1.13 (95% CI, 0.96-1.33); this OR was 1.07 (95% CI, 0.82-1.38) at dosages of 20 to 39.9 mg/d and 0.85 (95% CI, 0.47-1.53) at dosages of 40 mg/d or more. The adjusted OR was 0.71 (95% CI, 0.50-1.01) for statin use durations of 0 to 3 months, 1.31 (95% CI, 0.87-1.95) for durations of 3 to 6 months, 1.14 (95% CI, 0.82-1.58) for durations of 6 to 12 months, and 1.17 (95% CI, 0.99-1.40) for durations of more than 12 months.
Conclusion: In this study, use of statins at dosages prescribed in clinical practice was not associated with a reduction in risk of fracture.
Text
26060.pdf
- Version of Record
Restricted to Repository staff only
Request a copy
More information
Published date: 11 April 2001
Organisations:
Dev Origins of Health & Disease
Identifiers
Local EPrints ID: 26060
URI: http://eprints.soton.ac.uk/id/eprint/26060
ISSN: 0098-7484
PURE UUID: 50a5acc3-5bce-4f3d-9d96-a2586b722e32
Catalogue record
Date deposited: 24 Apr 2006
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
Tjeerd-Pieter van Staa
Author:
Sebastiaan Wegman
Author:
Frank de Vries
Author:
Bert Leufkens
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics
